156 related articles for article (PubMed ID: 12065099)
1. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer.
Levegrün S; Jackson A; Zelefsky MJ; Venkatraman ES; Skwarchuk MW; Schlegel W; Fuks Z; Leibel SA; Ling CC
Radiother Oncol; 2002 Apr; 63(1):11-26. PubMed ID: 12065099
[TBL] [Abstract][Full Text] [Related]
2. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data.
Levegrün S; Jackson A; Zelefsky MJ; Skwarchuk MW; Venkatraman ES; Schlegel W; Fuks Z; Leibel SA; Ling CC
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1064-80. PubMed ID: 11704332
[TBL] [Abstract][Full Text] [Related]
3. Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models.
Levegrün S; Jackson A; Zelefsky MJ; Venkatraman ES; Skwarchuk MW; Schlegel W; Fuks Z; Leibel SA; Ling CC
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1245-60. PubMed ID: 10889378
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
Perez CA; Michalski JM; Mansur D; Lockett MA
Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
[TBL] [Abstract][Full Text] [Related]
5. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
[TBL] [Abstract][Full Text] [Related]
6. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
7. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer.
Pinover WH; Hanlon AL; Horwitz EM; Hanks GE
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):649-54. PubMed ID: 10837947
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison.
Perez CA; Michalski JM; Purdy JA; Wasserman TH; Williams K; Lockett MA
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):629-37. PubMed ID: 10837945
[TBL] [Abstract][Full Text] [Related]
9. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
[TBL] [Abstract][Full Text] [Related]
10. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
11. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
Zelefsky MJ; Leibel SA; Gaudin PB; Kutcher GJ; Fleshner NE; Venkatramen ES; Reuter VE; Fair WR; Ling CC; Fuks Z
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):491-500. PubMed ID: 9635694
[TBL] [Abstract][Full Text] [Related]
13. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
[TBL] [Abstract][Full Text] [Related]
14. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Renshaw AA; Tomaszewski JE; Richie JP; Wein A
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1227-33. PubMed ID: 10613317
[TBL] [Abstract][Full Text] [Related]
15. Dose selection for prostate cancer patients based on dose comparison and dose response studies.
Hanks GE; Hanlon AL; Pinover WH; Horwitz EM; Price RA; Schultheiss T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):823-32. PubMed ID: 10705002
[TBL] [Abstract][Full Text] [Related]
16. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms.
Jackson A; Skwarchuk MW; Zelefsky MJ; Cowen DM; Venkatraman ES; Levegrun S; Burman CM; Kutcher GJ; Fuks Z; Liebel SA; Ling CC
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):685-98. PubMed ID: 11172950
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy.
Symon Z; Griffith KA; McLaughlin PW; Sullivan M; Sandler HM
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):384-90. PubMed ID: 12957249
[TBL] [Abstract][Full Text] [Related]
18. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.
Fukunaga-Johnson N; Sandler HM; McLaughlin PW; Strawderman MS; Grijalva KH; Kish KE; Lichter AS
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):311-7. PubMed ID: 9226317
[TBL] [Abstract][Full Text] [Related]
19. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
[TBL] [Abstract][Full Text] [Related]
20. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10).
Kupelian PA; Buchsbaum JC; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):621-5. PubMed ID: 11395228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]